Maria Lahuerta1,2, Roberta Sutton3, Anthony Mansaray4, Oliver Eleeza4, Brigette Gleason5, Adewale Akinjeji4, Mohamed F Jalloh6, Mame Toure4, Getachew Kassa3, Steven R Meshnick7, Molly Deutsch-Feldman7, Lauren Parmley3, Michael Friedman5, Samuel Juana Smith8, Miriam Rabkin3,9, Laura Steinhardt10. 1. ICAP at Columbia University, Mailman School of Public Health, New York, USA. ml2842@cumc.columbia.edu. 2. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, USA. ml2842@cumc.columbia.edu. 3. ICAP at Columbia University, Mailman School of Public Health, New York, USA. 4. ICAP at Columbia University, Freetown, Sierra Leone. 5. United States Centers for Disease Control and Prevention, Freetown, Sierra Leone. 6. Immunization Systems Branch, Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, USA. 7. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA. 8. National Malaria Control Program, Ministry of Health and Sanitation, Freetown, Sierra Leone. 9. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, USA. 10. Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, USA.
Abstract
BACKGROUND: Intermittent preventive treatment of malaria in infants (IPTi) with sulfadoxine-pyrimethamine (SP) is a proven strategy to protect infants against malaria. Sierra Leone is the first country to implement IPTi nationwide. IPTi implementation was evaluated in Kambia, one of two initial pilot districts, to assess quality and coverage of IPTi services. METHODS: This mixed-methods evaluation had two phases, conducted 3 (phase 1) and 15-17 months (phase 2) after IPTi implementation. Methods included: assessments of 18 health facilities (HF), including register data abstraction (phases 1 and 2); a knowledge, attitudes and practices survey with 20 health workers (HWs) in phase 1; second-generation sequencing of SP resistance markers (pre-IPTi and phase 2); and a cluster-sample household survey among caregivers of children aged 3-15 months (phase 2). IPTi and vaccination coverage from the household survey were calculated from child health cards and maternal recall and weighted for the complex sampling design. Interrupted time series analysis using a Poisson regression model was used to assess changes in malaria cases at HF before and after IPTi implementation. RESULTS: Most HWs (19/20) interviewed had been trained on IPTi; 16/19 reported feeling well prepared to administer it. Nearly all HFs (17/18 in phase 1; 18/18 in phase 2) had SP for IPTi in stock. The proportion of parasite alleles with dhps K540E mutations increased but remained below the 50% WHO-recommended threshold for IPTi (4.1% pre-IPTi [95%CI 2-7%]; 11% post-IPTi [95%CI 8-15%], p < 0.01). From the household survey, 299/459 (67.4%) children ≥ 10 weeks old received the first dose of IPTi (versus 80.4% for second pentavalent vaccine, given simultaneously); 274/444 (62.5%) children ≥ 14 weeks old received the second IPTi dose (versus 65.4% for third pentavalent vaccine); and 83/217 (36.4%) children ≥ 9 months old received the third IPTi dose (versus 52.2% for first measles vaccine dose). HF register data indicated no change in confirmed malaria cases among infants after IPTi implementation. CONCLUSIONS: Kambia district was able to scale up IPTi swiftly and provide necessary health systems support. The gaps between IPTi and childhood vaccine coverage need to be further investigated and addressed to optimize the success of the national IPTi programme.
BACKGROUND: Intermittent preventive treatment of malaria in infants (IPTi) with sulfadoxine-pyrimethamine (SP) is a proven strategy to protect infants against malaria. Sierra Leone is the first country to implement IPTi nationwide. IPTi implementation was evaluated in Kambia, one of two initial pilot districts, to assess quality and coverage of IPTi services. METHODS: This mixed-methods evaluation had two phases, conducted 3 (phase 1) and 15-17 months (phase 2) after IPTi implementation. Methods included: assessments of 18 health facilities (HF), including register data abstraction (phases 1 and 2); a knowledge, attitudes and practices survey with 20 health workers (HWs) in phase 1; second-generation sequencing of SP resistance markers (pre-IPTi and phase 2); and a cluster-sample household survey among caregivers of children aged 3-15 months (phase 2). IPTi and vaccination coverage from the household survey were calculated from child health cards and maternal recall and weighted for the complex sampling design. Interrupted time series analysis using a Poisson regression model was used to assess changes in malaria cases at HF before and after IPTi implementation. RESULTS: Most HWs (19/20) interviewed had been trained on IPTi; 16/19 reported feeling well prepared to administer it. Nearly all HFs (17/18 in phase 1; 18/18 in phase 2) had SP for IPTi in stock. The proportion of parasite alleles with dhps K540E mutations increased but remained below the 50% WHO-recommended threshold for IPTi (4.1% pre-IPTi [95%CI 2-7%]; 11% post-IPTi [95%CI 8-15%], p < 0.01). From the household survey, 299/459 (67.4%) children ≥ 10 weeks old received the first dose of IPTi (versus 80.4% for second pentavalent vaccine, given simultaneously); 274/444 (62.5%) children ≥ 14 weeks old received the second IPTi dose (versus 65.4% for third pentavalent vaccine); and 83/217 (36.4%) children ≥ 9 months old received the third IPTi dose (versus 52.2% for first measles vaccine dose). HF register data indicated no change in confirmed malaria cases among infants after IPTi implementation. CONCLUSIONS: Kambia district was able to scale up IPTi swiftly and provide necessary health systems support. The gaps between IPTi and childhood vaccine coverage need to be further investigated and addressed to optimize the success of the national IPTi programme.
Entities:
Keywords:
Coverage; Evaluation; Household survey; IPTi; Infants; Malaria; National scale-up; Sierra Leone
Authors: Christopher Pell; Lianne Straus; Suparat Phuanukoonnon; Sebeya Lupiwa; Ivo Mueller; Nicolas Senn; Peter Siba; Marjolein Gysels; Robert Pool Journal: Malar J Date: 2010-12-22 Impact factor: 2.979
Authors: R Matthew Chico; Jorge Cano; Cono Ariti; Timothy J Collier; Daniel Chandramohan; Cally Roper; Brian Greenwood Journal: Trop Med Int Health Date: 2015-09-30 Impact factor: 2.622
Authors: Julius J Massaga; Andrew Y Kitua; Martha M Lemnge; Jumaa A Akida; Lincoln N Malle; Anita M Rønn; Thor G Theander; Ib C Bygbjerg Journal: Lancet Date: 2003-05-31 Impact factor: 79.321
Authors: Martin P Grobusch; Bertrand Lell; Norbert G Schwarz; Julian Gabor; Jenny Dornemann; Marc Potschke; Sunny Oyakhirome; Georg C Kiessling; Magdalena Necek; Matthias U Langin; Peter Klein Klouwenberg; Anna Klopfer; Benjamin Naumann; Handan Altun; Selidji T Agnandji; Julia Goesch; Marieluise Decker; Carmen L Ospina Salazar; Christian Supan; Davy U Kombila; Lea Borchert; Kai B Koster; Peter Pongratz; Akim A Adegnika; Isabelle von Glasenapp; Saadou Issifou; Peter G Kremsner Journal: J Infect Dis Date: 2007-10-25 Impact factor: 5.226
Authors: Molly Deutsch-Feldman; Ozkan Aydemir; Margaret Carrel; Nicholas F Brazeau; Samir Bhatt; Jeffrey A Bailey; Melchior Kashamuka; Antoinette K Tshefu; Steve M Taylor; Jonathan J Juliano; Steven R Meshnick; Robert Verity Journal: BMC Infect Dis Date: 2019-10-22 Impact factor: 3.090
Authors: Ozkan Aydemir; Mark Janko; Nick J Hathaway; Robert Verity; Melchior Kashamuka Mwandagalirwa; Antoinette K Tshefu; Sofonias K Tessema; Patrick W Marsh; Alice Tran; Thomas Reimonn; Azra C Ghani; Anita Ghansah; Jonathan J Juliano; Bryan R Greenhouse; Michael Emch; Steven R Meshnick; Jeffrey A Bailey Journal: J Infect Dis Date: 2018-08-14 Impact factor: 5.226